Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)

• Company Description    Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. Number of Employees: 128

• Price / Volume Information    Yesterday's Closing Price: $23.88 Daily Weekly Monthly 20 Day Moving Average: 957,451 shares Shares Outstanding: 54.80 (millions) Market Capitalization: $1,308.56 (millions) Beta: 1.14 52 Week High: $24.00 52 Week Low: $5.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 39.08% 36.57% 12 Week 106.40% 87.39% Year To Date 116.50% 93.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 45 WIGGINS AVENUE - BEDFORD,MA 01730 USA ph: 781-430-8200 fax: - ir@stoketherapeutics.com http://www.stoketherapeutics.com

• General Corporate Information    Officers Edward M. Kaye - Chief Executive Officer Thomas E. Leggett - Chief Financial Officer Julie A. Smith - Director Adrian R. Krainer - Director Jennifer C. Burstein - Director Peer Information Stoke Therapeutics, Inc. (CORR.) Stoke Therapeutics, Inc. (RSPI) Stoke Therapeutics, Inc. (CGXP) Stoke Therapeutics, Inc. (BGEN) Stoke Therapeutics, Inc. (GTBP) Stoke Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 86150R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 54.80 Most Recent Split Date: (:1) Beta: 1.14 Market Capitalization: $1,308.56 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.30 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: 79.60 Trailing 12 Months: 28.09 PEG Ratio: - Price Ratios Price/Book: 3.89 Price/Cash Flow: - Price / Sales: 6.55 EPS Growth vs. Year Ago Period: 13.04% vs. Previous Quarter: -121.05% Sales Growth vs. Year Ago Period: 186.01% vs. Previous Quarter: -91.29% ROE 06/30/25 - 18.32 03/31/25 - 19.08 12/31/24 - -42.16 ROA 06/30/25 - 15.48 03/31/25 - 15.72 12/31/24 - -33.02 Current Ratio 06/30/25 - 6.98 03/31/25 - 8.41 12/31/24 - 5.81 Quick Ratio 06/30/25 - 6.98 03/31/25 - 8.41 12/31/24 - 5.81 Operating Margin 06/30/25 - 26.25 03/31/25 - 26.33 12/31/24 - -243.42 Net Margin 06/30/25 - 26.25 03/31/25 - 26.33 12/31/24 - -243.42 Pre-Tax Margin 06/30/25 - 26.90 03/31/25 - 27.00 12/31/24 - -243.42 Book Value 06/30/25 - 6.13 03/31/25 - 6.41 12/31/24 - 4.32 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©